Martin Münchbach

Martin is a founding partner of Pureos and has been a venture capital investor since 1999, investing in life science companies across all stages and types. Prior to Pureos, he was senior investment advisor private equity at Bellevue Asset Management. Martin’s most successful investments and board assignments include Radius Health, Molecular Partners, Optimer, Axovan and Glycart. Martin is currently a BoD member at Ypsomed Holding, Alentis Therapeutics, binX Health, River Renal and SatoSea Oncology. Martin obtained his PhD in protein chemistry from the ETH Zurich and his MAS in Management, Technology, and Economics from ETH Zurich.